Journal ArticleOPEN ACCESS

Baricitinib: a new oral treatment for rheumatoid arthritis

  • Chaplin S
Prescriber (2017) 28(6) 44-46
DOI: 10.1002/psb.1586
N/ACitations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Baricitinib (Olumiant) is a new oral janus kinase inhibitor licensed for the second‐line treatment of moderate to severe active rheumatoid arthritis. This article summarises its efficacy, side‐effects and place in therapy.

Cite

CITATION STYLE

APA

Chaplin, S. (2017). Baricitinib: a new oral treatment for rheumatoid arthritis. Prescriber, 28(6), 44–46. https://doi.org/10.1002/psb.1586

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free